

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

IN RE PCT NATIONAL STAGE APPLICATION OF                      Art Unit: 1616  
Kowalski, James et al.    Examiner: Yu, Hong  
INTERNATIONAL APPLICATION NO: PCT/EP2005/000400  
FILED: January 17, 2005  
U.S. APPLICATION NO: 10/586059  
35 USC §371 DATE: May 08, 2007  
FOR: Direct Compression Formulation and Process

**MS: Amendment**

Commissioner for Patents  
PO Box 1450  
Alexandria, VA 22313-1450

SUPPLEMENTAL INFORMATION DISCLOSURE STATEMENT

Sir:

This paper is being filed:

- ☒ supplemental to the Information Disclosure Statement filed March 13, 2008 and September 20, 2010.
- ☐ within three months of the date of entry of the national stage as set forth in 37 C.F.R. §1.491 of the international application. Therefore, no fees are required.
- ☐ before the mailing date of a first Office action on the merits, and so under 37 C.F.R. §1.97(b)(3) no fees are required.

If a fee is deemed to be required, the Commissioner is hereby authorized to charge such fee to Deposit Account No. 19-0134 in the name of Novartis.

- ☒ This Information Disclosure Statement is being filed in accordance with 37 C.F.R. §1.97(c) or 37 C.F.R. §1.97(d).
- ☒ A letter for payment of fee set forth in 37 C.F.R. §1.17(p) is enclosed.

In accordance with 37 C.F.R. §1.56, applicants wish to call the Examiner's attention to the references cited on the attached form(s) PTO/SB/08A/B.


- ☐ The listed references were cited in the international stage search report and copies are enclosed herewith except for the US patents/applications.
- ☒ Copies of the references are enclosed herewith.

The Examiner is requested to consider the foregoing information in relation to this application and indicate that each reference was considered by returning a copy of the initialed PTO/SB/08A/B form(s).

Novartis Pharmaceuticals Corporation  
One Health Plaza, Bldg. 101  
East Hanover, NJ 07936  
(862) 778-1422

Date: May 9, 2011

Respectfully submitted,



Stephen Johnson  
for Applicant  
Reg. No. 45,916

CASE PAT033554-US-PCT  
IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

IN RE PCT NATIONAL STAGE APPLICATION OF      Art Unit: 1616  
Kowalski, James et al.      Examiner: Yu, Hong  
INTERNATIONAL APPLICATION NO: PCT/EP2005/000400  
FILED: January 17, 2005  
U.S. APPLICATION NO: 10/586059  
35 USC §371 DATE: May 08, 2007  
FOR: Direct Compression Formulation and Process

Commissioner for Patents  
PO Box 1450  
Alexandria, VA 22313-1450

FEE LETTER FOR INFORMATION DISCLOSURE STATEMENT


Sir:

Please charge Deposit Account No. 19-0134 in the name of Novartis in the amount of \$180 for payment of the fee pursuant to 37 CFR §1.17(p) for the submission of an Information Disclosure Statement under 37 CFR §1.97(c).

The Commissioner is hereby authorized to charge any additional fees which may be required, or credit any overpayment, to Account No. 19-0134 in the name of Novartis.

Novartis Pharmaceuticals Corporation  
One Health Plaza, Bldg. 101  
East Hanover, NJ 07936  
(862) 778-1422  
Date: *May 9, 2011*

Respectfully submitted,

  
\_\_\_\_\_  
Stephen Johnson  
for Applicant  
Reg. No. 45,916